{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=27", "query": { "condition": "Non-small Cell Lung Carcinoma (NSCLC)", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 3556, "total_pages": 356, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:38:04.567Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Endometrial Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "FT836", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2025-11-04", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216105" }, { "nct_id": "NCT04982224", "title": "Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced NSCLC" ], "interventions": [ { "name": "REGN5093-M114", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-11-09", "completion_date": "2025-10-15", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 11, "location_summary": "Orange, California • Denver, Colorado • Baltimore, Maryland + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04982224" }, { "nct_id": "NCT03123783", "title": "CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Non Small Cell Lung Cancer Metastatic", "Metastatic Melanoma", "Neoplasm of Lung", "Melanoma" ], "interventions": [ { "name": "APX005M", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apexigen America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2017-07-10", "completion_date": "2020-11-16", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 13, "location_summary": "Tucson, Arizona • Duarte, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03123783" }, { "nct_id": "NCT01708954", "title": "Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2013-02-13", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 356, "location_summary": "Scottsdale, Arizona • Modesto, California • Monterey, California + 231 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Modesto", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708954" }, { "nct_id": "NCT06239194", "title": "Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Biliary Tract Cancer", "Breast Cancer", "Cervical Cancer", "Colon Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gastric Cancer", "GastroEsophageal Cancer", "Head and Neck Cancer", "Hepatocellular Cancer", "Non-small Cell Lung Cancer", "Pancreatic Cancer", "Prostate Cancer", "Rectal Cancer", "Renal Cancer", "Thyroid Cancer" ], "interventions": [ { "name": "MDX2001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ModeX Therapeutics, An OPKO Health Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2024-06-12", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 6, "location_summary": "Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239194" }, { "nct_id": "NCT00002656", "title": "Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "pyrazoloacridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1995-10", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2013-04-29", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002656" }, { "nct_id": "NCT04777994", "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor Cancer" ], "interventions": [ { "name": "ABBV-CLS-484", "type": "DRUG" }, { "name": "Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)", "type": "DRUG" }, { "name": "Programmed Cell Death-1 (PD-1) Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calico Life Sciences LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2021-03-09", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 15, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04777994" }, { "nct_id": "NCT06188702", "title": "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MTAP-deleted Solid Tumors" ], "interventions": [ { "name": "S095035", "type": "DRUG" }, { "name": "TNG462", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2024-04-29", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 5, "location_summary": "Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06188702" }, { "nct_id": "NCT02443337", "title": "A Study of LY3023414 and Necitumumab in Squamous Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "LY3023414", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2015-07", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 14, "location_summary": "Mobile, Alabama • Chandler, Arizona • Englewood, Colorado + 10 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443337" }, { "nct_id": "NCT03819296", "title": "Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage 0 Cutaneous Melanoma AJCC v8", "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Colitis", "Lung Non-Small Cell Carcinoma", "Malignant Genitourinary System Neoplasm", "Malignant Solid Neoplasm", "Pathologic Stage 0 Cutaneous Melanoma AJCC v8", "Pathologic Stage I Cutaneous Melanoma AJCC v8", "Pathologic Stage IA Cutaneous Melanoma AJCC v8", "Pathologic Stage IB Cutaneous Melanoma AJCC v8", "Pathologic Stage II Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIC Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage 0 Lung Cancer AJCC v8", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "OTHER" }, { "name": "Endoscopic Procedure", "type": "PROCEDURE" }, { "name": "Fecal Microbiota Transplantation", "type": "PROCEDURE" }, { "name": "Infliximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vedolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2021-02-21", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-14T12:38:04.567Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819296" } ] }